

21. (amended) The pharmaceutical composition of claim 14, wherein the composition is administered in the form selected from the group consisting of tablets, dragees, capsules, granules, solutions, suspensions and lyophilized compositions.

22. (amended) The pharmaceutical composition of claim 14 wherein the composition further comprises a fat-soluble antioxidant selected from the group consisting of ascorbyl palmitate, tocopherols, and ascorbic acid in the presence of lecithin.

23. (amended) The pharmaceutical composition of claim 14 wherein the composition further comprises an additive selected from the group consisting of aggregants, disaggregants, osmotic pressure regulating salts, buffers, sweeteners, and coloring agents.

27. (amended) The use of the pharmaceutical composition of claim 14 to treat:

- (a) cardiovascular or cerebrovascular disease
- (b) inflammatory or autoimmune disease
- (c) infection with bacteria, viruses, fungi, or protozoa,
- (d) respiratory disease
- (e) gastrointestinal disease
- (f) renal or urinary tract disease
- (g) skin disease
- (h) neurological or psychiatric disease
- (i) disease of the reproductive system
- (j) diabetes, syndrome A or any complication of diabetes

28. (amended) The use of the pharmaceutical composition of claim 14
to treat a disease or condition associated with overactive
protein kinases.

30. (amended) The use of the pharmaceutical composition of claim 14
to treat a disease or condition where endothelial function is
disordered.

31. (amended) The use of the pharmaceutical composition of claim 14
to treat cancer or the metastatic spread of cancer.

32. (amended) The use of the pharmaceutical composition of claim 14
to prevent cancer or the metastatic spread of cancer.

2000032200